Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: SRPT stock price vs BXP: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BXP's multiple
Needs BXP P/S.
Implied fair value · at SRPT's multiple
Needs SRPT P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SRPT FY 2025 (ended Dec 31, 2025) · BXP FY 2025 (ended Dec 31, 2025).
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
SAREPTA THERAPEUTICS, INC. · implied price per share
Bear
-$43.23
Base
-$50.86
Bull
-$58.48
BXP, INC. · implied price per share
Bear
$64.97
Base
$76.43
Bull
$87.90
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.82x
0.64x
Net debt / EBITDA
Leverage against operating earnings
0.01x
1.11x
Cash and equivalents
Liquid reserves on the balance sheet
$939.65M
$1.52B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
SRPT vs AMGN
BIOMARIN PHARMACEUTICAL INC
SRPT vs BMRN
Replimune Group, Inc.
SRPT vs REPL
PTC THERAPEUTICS, INC.
SRPT vs PTCT
COSTAR GROUP, INC.
SRPT vs CSGP
WELLTOWER INC.
SRPT vs WELL
UDR, Inc.
SRPT vs UDR
Prologis, Inc.
SRPT vs PLD
Public Storage
SRPT vs PSA
EQUITY RESIDENTIAL
SRPT vs EQR
$934.46M
$3.30B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe SRPT can convert its 15.6% revenue growth into sustainable positive margins and improve quality metrics from a 2/9 F-Score and -1.00 Z-Score, then the stock could merit accumulation because BXP-based P/S valuation implies substantial upside; otherwise, the current price near the historical band suggests the discount may be justified.
On a P/S basis, SRPT's current price of $19.28 sits far below BXP-implied value of $66.47, implying 244.8% upside. However, SRPT's own historical band of $17.35 to $21.21 shows the stock is currently trading near the top of its recent range rather than at a clear dislocation.
Supporting Metrics
